Humanigen Revenue and Competitors
Estimated Revenue & Valuation
- Humanigen's estimated annual revenue is currently $1.1M per year.
- Humanigen's estimated revenue per employee is $84,000
Employee Data
- Humanigen has 13 Employees.
- Humanigen grew their employee count by -32% last year.
Humanigen's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chairman, CEO | Reveal Email/Phone |
2 | Principal | Reveal Email/Phone |
Humanigen Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2M | 26 | 8% | $89.5M | N/A |
What Is Humanigen?
Humanigen, Inc. (HGEN) is a clinical-stage biopharmaceutical company seeking to transform the treatment of cancers and infectious diseases, including COVID-19, by preventing and treating cytokine storm via its novel, cutting-edge anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody neutralization and gene-knockout platforms. Its proprietary Humaneered® monoclonal antibodies, designed to optimize antibody properties, show promise in prevention/treatment of cytokine storm induced by SARS-CoV-2 (COVID-19), chimeric antigen receptor T-cell (CAR-T) therapy and graft versus host disease (GvHD) by neutralizing GM-CSF which is up-regulated in these conditions.
keywords:N/A
N/A
Total Funding
13
Number of Employees
$1.1M
Revenue (est)
-32%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Humanigen News
That average ranking earns Humanigen Inc an Analyst Rating of 29, which is better than 29% of stocks based on data compiled by InvestorsObserver...
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective...
Humanigen's monoclonal antibody lenzilumab is safe and effective for treating hospitalized patients with COVID-19, the results of a phase 3...
Other Companies in Burlingame
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 14 | -33% | N/A |
#2 | $1.3M | 15 | 50% | N/A |
#3 | $2M | 15 | 36% | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $0.8M | 15 | -62% | $38.5M |